Cargando…

Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study

INTRODUCTION: North America is amid an opioid use epidemic. Opioid agonist treatment (OAT) effectively reduces extramedical opioid use and related harms. As with all pharmacological treatments, there are risks associated with OAT, including fatal overdose. There is a need to better understand risk f...

Descripción completa

Detalles Bibliográficos
Autores principales: Larney, Sarah, Hickman, Matthew, Fiellin, David A, Dobbins, Timothy, Nielsen, Suzanne, Jones, Nicola R, Mattick, Richard P, Ali, Robert, Degenhardt, Louisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078240/
https://www.ncbi.nlm.nih.gov/pubmed/30082370
http://dx.doi.org/10.1136/bmjopen-2018-025204
_version_ 1783345057296809984
author Larney, Sarah
Hickman, Matthew
Fiellin, David A
Dobbins, Timothy
Nielsen, Suzanne
Jones, Nicola R
Mattick, Richard P
Ali, Robert
Degenhardt, Louisa
author_facet Larney, Sarah
Hickman, Matthew
Fiellin, David A
Dobbins, Timothy
Nielsen, Suzanne
Jones, Nicola R
Mattick, Richard P
Ali, Robert
Degenhardt, Louisa
author_sort Larney, Sarah
collection PubMed
description INTRODUCTION: North America is amid an opioid use epidemic. Opioid agonist treatment (OAT) effectively reduces extramedical opioid use and related harms. As with all pharmacological treatments, there are risks associated with OAT, including fatal overdose. There is a need to better understand risk for adverse outcomes during and after OAT, and for innovative approaches to identifying people at greatest risk of adverse outcomes. The Opioid Agonist Treatment and Safety study aims to address these questions so as to inform the expansion of OAT in the USA. METHODS AND ANALYSIS: This is a retrospective cohort study using linked, routinely collected health data for all people seeking OAT in New South Wales, Australia, between 2001 and 2017. Linked data include hospitalisation, emergency department presentation, mental health diagnoses, incarceration and mortality. We will use standard regression techniques to model the magnitude and risk factors for adverse outcomes (eg, mortality, unplanned hospitalisation and emergency department presentation, and unplanned treatment cessation) during and after OAT, and machine learning approaches to develop a risk-prediction model. ETHICS AND DISSEMINATION: This study has been approved by the Population and Health Services Research Ethics Committee (2018HRE0205). Results will be reported in accordance with the REporting of studies Conducted using Observational Routinely-collected health Data statement.
format Online
Article
Text
id pubmed-6078240
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-60782402018-08-09 Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study Larney, Sarah Hickman, Matthew Fiellin, David A Dobbins, Timothy Nielsen, Suzanne Jones, Nicola R Mattick, Richard P Ali, Robert Degenhardt, Louisa BMJ Open Addiction INTRODUCTION: North America is amid an opioid use epidemic. Opioid agonist treatment (OAT) effectively reduces extramedical opioid use and related harms. As with all pharmacological treatments, there are risks associated with OAT, including fatal overdose. There is a need to better understand risk for adverse outcomes during and after OAT, and for innovative approaches to identifying people at greatest risk of adverse outcomes. The Opioid Agonist Treatment and Safety study aims to address these questions so as to inform the expansion of OAT in the USA. METHODS AND ANALYSIS: This is a retrospective cohort study using linked, routinely collected health data for all people seeking OAT in New South Wales, Australia, between 2001 and 2017. Linked data include hospitalisation, emergency department presentation, mental health diagnoses, incarceration and mortality. We will use standard regression techniques to model the magnitude and risk factors for adverse outcomes (eg, mortality, unplanned hospitalisation and emergency department presentation, and unplanned treatment cessation) during and after OAT, and machine learning approaches to develop a risk-prediction model. ETHICS AND DISSEMINATION: This study has been approved by the Population and Health Services Research Ethics Committee (2018HRE0205). Results will be reported in accordance with the REporting of studies Conducted using Observational Routinely-collected health Data statement. BMJ Publishing Group 2018-08-05 /pmc/articles/PMC6078240/ /pubmed/30082370 http://dx.doi.org/10.1136/bmjopen-2018-025204 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Addiction
Larney, Sarah
Hickman, Matthew
Fiellin, David A
Dobbins, Timothy
Nielsen, Suzanne
Jones, Nicola R
Mattick, Richard P
Ali, Robert
Degenhardt, Louisa
Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study
title Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study
title_full Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study
title_fullStr Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study
title_full_unstemmed Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study
title_short Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study
title_sort using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: protocol for the opioid agonist treatment safety (oats) study
topic Addiction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078240/
https://www.ncbi.nlm.nih.gov/pubmed/30082370
http://dx.doi.org/10.1136/bmjopen-2018-025204
work_keys_str_mv AT larneysarah usingroutinelycollecteddatatounderstandandpredictadverseoutcomesinopioidagonisttreatmentprotocolfortheopioidagonisttreatmentsafetyoatsstudy
AT hickmanmatthew usingroutinelycollecteddatatounderstandandpredictadverseoutcomesinopioidagonisttreatmentprotocolfortheopioidagonisttreatmentsafetyoatsstudy
AT fiellindavida usingroutinelycollecteddatatounderstandandpredictadverseoutcomesinopioidagonisttreatmentprotocolfortheopioidagonisttreatmentsafetyoatsstudy
AT dobbinstimothy usingroutinelycollecteddatatounderstandandpredictadverseoutcomesinopioidagonisttreatmentprotocolfortheopioidagonisttreatmentsafetyoatsstudy
AT nielsensuzanne usingroutinelycollecteddatatounderstandandpredictadverseoutcomesinopioidagonisttreatmentprotocolfortheopioidagonisttreatmentsafetyoatsstudy
AT jonesnicolar usingroutinelycollecteddatatounderstandandpredictadverseoutcomesinopioidagonisttreatmentprotocolfortheopioidagonisttreatmentsafetyoatsstudy
AT mattickrichardp usingroutinelycollecteddatatounderstandandpredictadverseoutcomesinopioidagonisttreatmentprotocolfortheopioidagonisttreatmentsafetyoatsstudy
AT alirobert usingroutinelycollecteddatatounderstandandpredictadverseoutcomesinopioidagonisttreatmentprotocolfortheopioidagonisttreatmentsafetyoatsstudy
AT degenhardtlouisa usingroutinelycollecteddatatounderstandandpredictadverseoutcomesinopioidagonisttreatmentprotocolfortheopioidagonisttreatmentsafetyoatsstudy